DDIT3 and diffuse large B-cell lymphoma: In a phase III randomized trial in DLBCL patients with c‐myc/bcl2 double expression, chidamide plus R‐CHOP resulted in a higher CR rate (73.0% versus 61.8%) and 24‐month EFS rate (58.9% versus 46.2%) compared with the control (R‐CHOP plus placebo) [50].